HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up

Article Information

DOI 
http://dx.doi.org/10.1177/155989771220005
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2013 MD Conference Express®

Author Information

  1. Emma Hitt Nichols, PhD
  1. Martine J. Piccart-Gebhart, MD, PhD
    1. Université Libre de Bruxelle and Jules Bordet Institute, Brussels, Belgium
View Full Text

Article usage

AbstractFullPDF
Apr 2015700
May 2015100
Jun 2015300
Jul 2015511
Aug 2015200
Sep 2015300
Oct 2015134
Nov 2015100
Total2345

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Oncology Genomics
Breast Cancer
Oncology Clinical Trials